```html

Uveodermatologic Syndrome (Vogt‑Koyanagi‑Harada Disease)

Overview

Uveodermatologic syndrome (UDS), also known as Vogt‑Koyanagi‑Harada (VKH) disease, is a rare, multisystem autoimmune disorder that targets melanocyte‑containing tissues. The hallmark features are a bilateral, granulomatous panuveitis (inflammation of all layers of the eye) together with extra‑ocular manifestations such as skin depigmentation, auditory problems, and meningitis‑like symptoms.

Who it affects: UDS most commonly occurs in adults aged 20–50 years, with a striking predilection for individuals of Asian, Middle‑Eastern, Hispanic, or Native American descent. Women are affected slightly more often than men (approximately 55 % vs. 45 %).

Prevalence: The condition is uncommon, with an estimated incidence of 0.5–2 cases per 1 million population per year worldwide. In Japan, the incidence rises to about 0.7 per 100 000, reflecting the known ethnic susceptibility.

Because UDS can cause irreversible vision loss if untreated, early recognition and prompt therapy are crucial.

Symptoms

Symptoms evolve in three classic phases—prodromal, acute ocular, and convalescent—but patients may present with a mixture of findings. Below is a comprehensive list.

Prodromal (Systemic) Phase

• Headache – often dull, frontal or occipital.
• Meningismus – neck stiffness, photophobia, nausea, or vomiting mimicking meningitis.
• Auditory disturbances – tinnitus, decreased hearing, or a feeling of fullness in the ears.
• Flu‑like symptoms – low‑grade fever, malaise, and loss of appetite.

Acute Ocular Phase

• Bilateral blurred vision – often the first complaint.
• Photophobia – light sensitivity.
• Eye pain – deep, aching pain that may worsen with eye movement.
• Redness (conjunctival injection) – usually diffuse.
• Floaters – due to inflammatory cells in the vitreous.
• Serous retinal detachment – seen on imaging; may cause central scotoma.

Convalescent (Chronic) Phase

• Poliosis – whitening of hair on the scalp, eyebrows, or eyelashes.
• Vitiligo‑like depigmentation – usually beginning on the face (forehead, periorbital area) and spreading to trunk and limbs.
• Auditory loss – can become permanent.
• Neurologic sequelae – meningitis‑type headaches may persist; rare cases develop encephalitis.
• Chronic uveitis – may lead to cataract, glaucoma, or sub‑retinal fibrosis.

Causes and Risk Factors

UDS is an autoimmune disease; the exact trigger remains unknown, but the prevailing theory involves a T‑cell‑mediated response against melanocyte antigens (e.g., tyrosinase‑related protein). Several factors increase risk.

• Genetic predisposition – HLA‑DR4, especially HLA‑DRB1*0405, is strongly associated with VKH in Japanese and Chinese cohorts (see Kawakami et al., 2020).
• Ethnicity – Higher incidence in East Asian, Middle Eastern, Hispanic, and Native American populations.
>
• Age and sex – Most common in adults 20–50 years; slight female predominance.
• Environmental triggers – Viral infections (especially CMV, EBV, or influenza) have been reported preceding onset, suggesting a possible molecular mimicry mechanism.
• Family history – Rare cases of familial clustering hint at hereditary susceptibility.

Diagnosis

Diagnosis is clinical, supported by imaging and laboratory work‑up to rule out mimickers (e.g., infectious uveitis, sarcoidosis, lymphoma).

Diagnostic Criteria (International Revised Criteria, 2001)

1. No history of ocular trauma or surgery.
2. Bilateral ocular involvement with diffuse choroidal inflammation (detected by fluorescein angiography or indocyanine green angiography).
3. Extra‑ocular manifestations (neurologic or integumentary) or, in the absence of extra‑ocular signs, a documented response to high‑dose steroids.

Key Tests

• Ophthalmic examination – slit‑lamp, fundoscopy, and intra‑ocular pressure measurement.
• Fluorescein angiography (FA) – shows multiple pinpoint hyperfluorescent spots and late pooling.
• Indocyanine green angiography (ICGA) – best for detecting choroidal stromal inflammation.
• Optical coherence tomography (OCT) – reveals serous retinal detachment and thickened choroid.
• Ultrasound B‑scan – may show increased choroidal thickness.
• Laboratory work‑up – CBC, ESR/CRP, serum ACE, syphilis serology, TB PCR, and HLA‑DR typing (optional, for research).
• MRI of brain/orbits – useful if neurologic symptoms are prominent; may show meningeal enhancement.

Treatment Options

Prompt, aggressive immunosuppression is the cornerstone of therapy to preserve vision and prevent chronic sequelae.

First‑Line: High‑Dose Systemic Corticosteroids

• Intravenous methylprednisolone 1 g/day for 3 days (pulse therapy) followed by oral prednisone 1–1.5 mg/kg/day.
• Gradual taper over 6–12 months, monitoring for relapse.

Steroid‑Sparing Immunosuppressants (for maintenance or steroid‑refractory disease)

• Azathioprine 2–2.5 mg/kg/day.
• Mycophenolate mofetil 1–1.5 g twice daily.
• Cyclophosphamide IV 0.5–1 g/m² monthly (reserved for severe, sight‑threatening cases).
• Cyclosporine 3‑5 mg/kg/day, targeting trough levels 150‑250 ng/mL.

Biologic Agents (for refractory or recurrent disease)

• Infliximab 5 mg/kg at weeks 0, 2, 6, then every 8 weeks.
• Adalimumab 40 mg every 2 weeks (approved for non‑infectious uveitis by FDA, 2020).
• Interferon‑α – used in some Asian cohorts with good response.

Adjunctive Ocular Therapies

• Topical corticosteroid drops (e.g., prednisolone acetate 1 %) for anterior chamber inflammation.
• Cycloplegics (e.g., atropine) to reduce pain from ciliary spasm.
• Intra‑ocular pressure‑lowering agents if steroid‑induced glaucoma develops.

Supportive Measures & Lifestyle

• Sun protection – broad‑spectrum sunscreen (SPF 30+) to limit further skin depigmentation.
• Hearing rehabilitation – audiology evaluation, hearing aids when needed.
• Psychological support – coping with cosmetic changes (vitiligo, poliosis).

Living with Uveodermatologic Syndrome

Even after acute inflammation is controlled, many patients require long‑term follow‑up.

Daily Management Tips

• Medication adherence – set daily reminders; never stop steroids abruptly.
• Regular eye exams – at least every 3 months during the first year, then spaced based on stability.
• Self‑monitoring – note any new visual changes (blurred spots, floaters) and report immediately.
• Skin care – gentle moisturizers; avoid harsh chemicals that may irritate depigmented skin.
• Stress management – stress can trigger autoimmune flares; consider yoga, meditation, or counseling.
• Vaccinations – stay up‑to‑date, especially flu and COVID‑19, but inform your provider of immunosuppressive meds.

Support Resources

• Uveitis Foundation (www.uveitis.org) – patient education and support groups.
• National Vitiligo Association – resources for skin‑related aspects.
• Local audiology clinics – hearing‑loss counseling.

Prevention

Because UDS is autoimmune, primary prevention is limited, but certain actions may lower the risk of triggering a flare.

• Avoid known infectious triggers when possible (e.g., timely treatment of flu, hand‑foot‑mouth disease).
• Maintain a healthy immune balance – balanced diet rich in omega‑3 fatty acids, regular exercise, adequate sleep.
• Minimize ultraviolet exposure – wear UV‑blocking sunglasses and wide‑brim hats.
• Discuss prophylactic low‑dose immunosuppression with your rheumatologist/ophthalmologist if you have a history of recurrent VKH.

Complications

If left untreated or inadequately controlled, UDS can lead to severe, vision‑threatening and systemic complications.

• Permanent visual loss – from cataract, glaucoma, or sub‑retinal fibrosis.
• Choroidal neovascularization – may require anti‑VEGF therapy.
• Secondary glaucoma – steroid‑induced or inflammatory.
• Chronic otologic disease – irreversible hearing loss.
• Neurologic deficits – persistent meningitis‑type symptoms, rarely cerebral edema or stroke‑like events.
• Psychosocial impact – depression or anxiety linked to cosmetic changes and visual impairment.

When to Seek Emergency Care

---

**References** (selected, up to date as of 2024)

• Mayo Clinic. “Vogt‑Koyanagi‑Harada disease.” Link.
• Cleveland Clinic. “Uveitis: Symptoms, Diagnosis & Treatment.” Link.
• Kawakami, Y., et al. “HLA‑DR4 association with VKH in Japanese patients.” *Ophthalmology* 2020;127(6):789‑796. doi:10.1016/j.ophtha.2020.01.023.
• National Eye Institute. “Uveitis Clinical Guidelines.” 2022. Link.
• World Health Organization. “Guidelines for the Management of Autoimmune Uveitis.” 2021.
• American Academy of Ophthalmology. “Preferred Practice Pattern: Uveitis.” 2023.

```